LivaNova (NSDQ:LIVN) eked out an earnings beat for its 1st full year as a public company, despite missing expectations for its top line, but share prices still fell today in early trading. LivaNova, formed by the $3 billion merger of Sorin Group and Cyberonics in 2015, posted losses of -$29.8 million, or -61¢ per share, on sales of $310.6 million […]
Wall Street Beat
Intersect ENT reels in losses, beats revenue estimates for Q4
Shares in Intersect ENT (NSDQ:XENT) fell slightly today even though the drug-device company met expectations on Wall Street with its 4th quarter results. The Menlo Park, Calif.-based company pared losses to -$4.8 million, or -17¢ per share, on sales of $24.2 million for the 3 months ended Dec. 31, for bottom-line growth of 15.8% on sales growth […]
DexCom beats Street with Q4 earnings
Shares in DexCom Inc. (NSDQ:DXCM) rose today after the medical device maker met expectations on Wall Street with its 4th quarter results. The San Diego-based company posted a loss of -$7.4 million, or -9¢ per share, on sales of $171.2 million for the 3 months ended Dec. 31, for bottom-line loss of -593.3% on sales growth […]
Alere slides after revealing new Asia accounting snafu
UPDATED March 1, 2017, with analyst comment, share price. Alere (NYSE:ALR) said today that it’s once again unable to file its annual report by the deadline, after an ongoing probe into its accounting practices turned up yet another irregularity, this time with how it recognized revenues in Asia. The news adds fuel to the fire over the […]
BioCardia, Johns Hopkins treats first patient with CardiAmp cell therapy in Phase III trial
Johns Hopkins, the Maryland Stem Cell Research Fund and BioCardia (NSDQ:BCDA) said today that the 1st patient has been treated in a pivotal Phase III trial of the CardiAmp cell-based therapy for the treatment of ischemic heart failure. The investigational therapy was designed to deliver a dose of a patient’s own bone marrow cells directly […]
Synergy Biomedical wins CE Mark for Biosphere putty
Synergy Biomedical said today that it won CE Mark clearance in the European Union for its Biosphere putty bone graft. The company’s Biosphere putty is a synthetic bone graft that uses a type of bioactive glass in combination with a moldable phospholipid carrier. Previous in vitro studies have shown that the bone graft product can significantly […]
FDA asks Titan for more info before clinical trial of ropinirole implant
Titan Pharmaceuticals (NSDQ:TTNP) said today that the FDA put a hold on the clinical trial of its ropinirole implant and told the company to submit more information to the federal watchdog. After it completed an initial review of the implant’s Investigational New Drug application, the FDA asked Titan for final release test data on its ropinirole […]
Insulet slides on Q4 earnings miss
Insulet (NSDQ:PODD) shares are under pressure this morning after the diabetes company missed expectations for its 4th-quarter earnings, despite beating Wall Street’s consensus sales forecast. Billerica, Mass.-based Insulet narrowed its losses by -66.6%, to -$9.1 million, or -16¢ per share, on sales growth of 23.6% to $103.6 million for the 3 months ended Dec. 31, compared […]
TearLab readies for reverse split
Shares in TearLab Corp. (NSDQ:TEAR) said last week that its board approved a 1-for-1 reverse split of its common stock. The company’s shares have fallen nearly 20% since the beginning of the month. The San Diego, Calif.-based company’s move reduced the total number of authorized shares of its common stock from 95 million t0 9.5 […]
Elixir Medical’s DeSyne stent tops Medtronic’s Endeavor after 5 years
Elixir Medical‘s novolimus-eluting stent, DeSyne, outperformed Medtronic‘s (NYSE:MDT) zotarolimus-eluting stent, Endeavor, according to long-term data from Elixir’s Excella II trial. The study enrolled 210 patients with 2 or more de novo lesions in 2 different epicardial vessels. Researchers randomly assigned patients in a 2:1 ratio to the novolimus-eluting stent or the zotarolimus-eluting stent. Get the full story at […]
Boston Scientific gets in on $45m private placement for Corindus Vascular Robotics
Boston Scientific (NYSE:BSX) got in on a $45 million private placement for Corindus Vascular Robotics (NYSE:CVRS) and the CorPath GRX device it’s developing for cardiac and peripheral vascular procedures. New investors BioStar Ventures, Consonance Capital and Hudson Executive Capital also participated, joining existing backers HealthCor Partners Management and Royal Philips (NYSE:PHG). “We are pleased to announce this financing and appreciate […]